Form 4: Royalty Pharma EVP Marshall Urist Sells Shares

EVP of Research & Investments Marshall Urist sold 13,684 Class A Ordinary Shares of Royalty Pharma plc via a 10b5-1 plan.

Summary

• Marshall Urist, EVP of Research & Investments at Royalty Pharma, sold 13,684 Class A Ordinary Shares.
• The shares were sold at a weighted average price of $53.0647 per share.
• The transaction was executed on May 14, 2026, pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2026.
• Following the sale, the reporting person retains direct ownership of 31,881 shares and indirect ownership of 19,020 shares via an IRA.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was pre-planned and represents a standard liquidity event for an executive.

Positives

• The sale was conducted under a pre-arranged 10b5-1 trading plan, which is a standard mechanism for executives to sell shares without concerns regarding insider trading.

Negatives

• The sale represents a reduction in the direct equity stake held by a key member of the executive leadership team.

Risks

• Future share price volatility may impact the value of the remaining 2,474,120 shares exchangeable from limited partnership interests and 1,356,528 shares from Class E Ordinary Shares.

Future Outlook

No specific forward-looking guidance regarding company performance was provided in this filing.

Industry Context

StockSavvy.ai notes that executive share sales under 10b5-1 plans are routine corporate governance events and generally do not signal a change in company fundamentals or management sentiment.

Comparison to Industry Standards

• The use of 10b5-1 plans is the industry standard for corporate insiders to manage personal liquidity while maintaining regulatory compliance.

Stakeholder Impact

• Minimal impact expected on shareholders as the sale was executed via a pre-arranged plan.

Key Dates

Keywords

Royalty Pharma, RPRX, Insider Trading, Form 4, Marshall Urist, Equity Sale